How do GLP-1 agonists actually cause fat loss beyond appetite suppression?

Reduced food intake is a major driver of the weight loss, and that is itself a biological effect. GLP-1 receptor activation changes signals involved in hunger, fullness, and eating behavior. In a controlled semaglutide study, participants reported less hunger and better control of eating and consumed less energy at a test meal. This is more specific than simply telling someone to eat less: the medication changes the signals that make doing so difficult.[1]

GLP-1 drugs also influence glucose regulation. Semaglutide increases insulin release and reduces glucagon when glucose is elevated, and it can slow stomach emptying. These effects help control blood sugar; they should not be described as proof that the drug directly burns large amounts of fat independently of food intake. Tirzepatide activates both GIP and GLP-1 receptors, so its biology is not identical to semaglutide’s.[2][3]

Over time, lower energy intake allows the body to draw on stored energy, including fat. Weight loss can also include lean tissue. Improvements in insulin sensitivity or cardiovascular outcomes matter, but they do not establish that each benefit is caused by an increased metabolic rate. The useful distinction is between demonstrated changes in appetite and glucose handling, and still-unresolved contributions of other pathways to total fat loss.[1][2]